MDA Space Beats Q3 2026 Estimates as Revenue Rises 19% to $349.8M
Revenue of $349.8M vs. $312.8M expected and adjusted EPS of $0.26 vs. $0.20; revenue up 19% from a year earlier.
MDA Space (MDA) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $349.8 million, up 19% from a year earlier, above the $312.8 million estimate, and adjusted EPS was $0.26, up 3.5% from a year earlier, above the $0.20 estimate.
Shares rose 0.7% in regular trading as of 10:10 a.m. ET, at $27.03.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | $0.20 | $0.26 | Beat by 30% |
| Revenue | $312.8M | $349.8M | Beat by 12% |
| Change | YoY | QoQ |
|---|---|---|
| Adjusted EPS | ▲ 3.5% | Unchanged |
| Revenue | ▲ 19% | ▼ 0.3% |
By our calculation, revenue was $37.0 million above the estimate and adjusted EPS was $0.06 above it. The QoQ column compares with the previous quarter's revenue of $351.0 million and adjusted EPS of $0.26. The YoY column compares with $294.2 million and $0.25 in the same quarter a year earlier.
Track record
- EPS record. Adjusted EPS beat the estimate in 7 of the last 8 reports, including this one.
- Revenue record. Revenue beat the estimate in 7 of the last 8 reports.
- Revenue trend. Revenue over the last 5 reports, oldest first: $294.2 million, $363.4 million, $333.7 million, $351.0 million and $349.8 million.
What to watch
- Next-quarter estimates. Consensus calls for EPS of $0.21 and revenue of $330.7 million next quarter, based on 8 analysts.
- Next report. MDA Space is next expected to report on March 11, 2027.
- Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 19% increase to $349.8 million.
- Related coverage. See our reports on Immunocore, Essent, Franklin Resources and VEON.
Sources: Results are from MDA Space's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from MDA Space's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
Immunocore Misses Q3 2026 Estimates as Revenue Falls 1.4% to $102.2M
EarningsEssent Q3 2026 Revenue Tops Estimates at $374.2M, but EPS Misses at $1.82
EarningsFranklin Resources Beats Fiscal Q4 2026 Estimates as Revenue Rises 3.9% to $2.43B
EarningsVEON Tops Q3 2026 Estimates as Revenue Rises 17% to $1.307B
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.